03:49 , Aug 17, 2018 |  BC Week In Review  |  Company News

CVS to launch ICER-restricted formulary

CVS Health Corp. (NYSE:CVS) plans to offer a new formulary restricted to drugs deemed cost-effective by the Institute for Clinical and Economic Review (ICER). CVS believes the formulary will pressure manufacturers to moderate launch prices...
22:35 , Aug 14, 2018 |  BC Extra  |  Company News

CVS to launch ICER-restricted formulary

CVS Health Corp. (NYSE:CVS) plans to offer a new formulary restricted to drugs deemed cost-effective by the Institute for Clinical and Economic Review (ICER). CVS believes the formulary will pressure manufacturers to moderate launch prices...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
20:41 , Jan 5, 2018 |  BC Week In Review  |  Company News

ICER issues affordability and access alert for tardive dyskinesia drugs

The Institute for Clinical and Economic Review issued an affordability and access alert for tardive dyskinesia drugs Ingrezza valbenazine (MT-5199, NBI-98854) and Austedo deutetrabenazine (SD-809), saying the drugs far exceed ICER’s budget impact threshold at...
19:05 , Dec 15, 2017 |  BC Week In Review  |  Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) disclosed details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%, to 39,000 over the next two years. Teva expects the cuts,...
22:29 , Dec 14, 2017 |  BC Extra  |  Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) gained $1.60 (10%) to $17.30 in New York on Thursday after disclosing details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%,...
00:32 , Nov 22, 2017 |  BC Extra  |  Politics & Policy

ICER says price of tardive dyskinesia drugs far exceed benefit

In an evidence report released Tuesday, the Institute for Clinical and Economic Review said the prices of tardive dyskinesia drugs Ingrezza valbenazine and Austedo deutetrabenazine need to be discounted by about 90% to align with...
20:22 , Nov 3, 2017 |  BioCentury  |  Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its reviews...
15:01 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

FDA approves Teva's Austedo for tardive dyskinesia

FDA approved Austedo deutetrabenazine (SD-809) from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to treat tardive dyskinesia in adults. Austedo is already approved in the U.S. to treat chorea associated with Huntington’s disease (HD). The product...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...